

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

	EV DIG DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
APPLICATION NO.	FILING DATE		2936.104/00	1612
08/983,605	05/01/1998	MARION RODER	2930.104/00	***-
7	590 04/11/2002			
Norris, McLaughlin & Marcus P. A.			EXAMINER	
220 East 42nd 30th Floor	Street		CHAKRABAI	RTI, ARUN K
New York, NY 10017			ART UNIT	PAPER NUMBER
			1634	
			DATE MAILED: 04/11/2002	2 20

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
•	08/983,605	RODER ET AL.
Office Action Summary	Examiner	Art Unit
	Arun Chakrabarti	1634
The MAILING DATE of this communi Period for Reply	cation appears on the cover sheet wit	h the correspondence address
A SHORTENED STATUTORY PERIOD FO THE MAILING DATE OF THIS COMMUNIO - Extensions of time may be available under the provisions of after SIX (6) MONTHS from the mailing date of this commoder in the period for reply specified above is less than thirty (30). If the period for reply is specified above, the maximum states a Failure to reply within the set or extended period for reply and the Any reply received by the Office later than three months after earned patent term adjustment. See 37 CFR 1.704(b).	CATION.  of 37 CFR 1.136(a). In no event, however, may a re unication.  o) days, a reply within the statutory minimum of thirty tutory period will apply and will expire SIX (6) MONT will, by statute, cause the application to become ABA	eply be timely filed  (30) days will be considered timely.  FHS from the mailing date of this communication.  ANDONED (35 U.S.C. § 133).
1) Responsive to communication(s) file	ed on <u>19 <i>February</i> 2002</u> .	
2a)⊠ This action is <b>FINAL</b> .	2b)  This action is non-final.	
	for allowance except for formal mattice under <i>Ex parte Quayle</i> , 1935 C.D	
4)⊠ Claim(s) <u>14-17</u> is/are pending in the	application.	
4a) Of the above claim(s) is/ar		
5) Claim(s) is/are allowed.		
6)⊠ Claim(s) <u>14-17</u> is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) are subject to restrict	tion and/or election requirement.	
Application Papers		
9) The specification is objected to by the	Examiner.	
10) The drawing(s) filed on is/are:	a) accepted or b) objected to by the	ıe Examiner.
Applicant may not request that any obje	ection to the drawing(s) be held in abeya	nce. See 37 CFR 1.85(a).
11)☐ The proposed drawing correction filed	on is: a) approved b) di	sapproved by the Examiner.
If approved, corrected drawings are rec	uired in reply to this Office action.	
12)☐ The oath or declaration is objected to	by the Examiner.	
Priority under 35 U.S.C. §§ 119 and 120		
13) Acknowledgment is made of a claim	for foreign priority under 35 U.S.C. §	119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:		
1. Certified copies of the priority of	documents have been received.	
2. Certified copies of the priority of	documents have been received in Ap	oplication No
	of the priority documents have been rational Bureau (PCT Rule 17.2(a)). In for a list of the certified copies not r	
14) Acknowledgment is made of a claim for	or domestic priority under 35 U.S.C. {	§ 119(e) (to a provisional application)
a)  The translation of the foreign lan	guage provisional application has be	een received.
15) Acknowledgment is made of a claim fo	or domestic priority under 35 U.S.C.	33 120 and/or 121.
Attachment(s)	4) T Intention C	Summary (PTO-413) Paper No(s)
Notice of References Cited (PTO-892)   Notice of Draftsperson's Patent Drawing Review (Pignation Disclosure Statement(s) (PTO-1449) Page   Properties   PTO-1449   PTO-1449	TO-948) 5) Notice of Ir	nformal Patent Application (PTO-152)

U.S. Patent and Trademark Office

Art Unit: 1634

#### **DETAILED ACTION**

### Specification

1. Claims 14-16 have been amended.

## Claim Rejections - 35 USC § 103

- 2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CAR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103© and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

3. Claims 14 and 17 are rejected over Morgante et al. (U.S. Patent 5,955,276) (September 21, 1991) in view of Mets et al. (U.S. Patent 5,332,408) (July 26, 1994).

Art Unit: 1634

Morgante et al teach a method of genotyping plants at a microsatellite locus (Abstract),

the method comprising;

a) amplifying chromosomal DNA with oligonucleotide primer pairs specifically

hybridizing to the locus of a region of the chromosomal DNA, wherein the region of the DNA

comprises a repeated dinucleotide motif comprising at least one of the following selected from

the group consisting of (GA:CT)n, (GT:CA)n, (AT:TA)n, to obtain an amplification product

(Column 26, line 60 to column 30, line 13 and Claim 1 and Table II),

b) size fractionating the amplification product to provide a measure of the motif of the

chromosomal DNA between the primer pairs (Figures 2-6),

wherein the size of the amplification product is polymorphic for the locus and provides a

genotype for the plants (Figures 2-6 and Column 34, line 45 to Column 36, line 24 and Examples

1-3).

Morgante et al teach a method further comprising the step of using the resulting genotype

for a further step chosen from genome fingerprinting and whole genome comparisons (Column 6,

lines 3-13).

Morgante et al do not teach a method of genotyping plants of the Triticum aestivum

species.

Mets et al teach the plants of the Triticum aestivum species (Column 5, lines 50-58).

It would have been prima facie obvious to one having ordinary skill in the art at the time

the invention was made to combine and substitute the plants of the Triticum aestivum species of

Page 3

Page 4

Art Unit: 1634

Mets et al. into the method of genotyping plants of Morgante et al., since Mets et al. state, "Existing crop plants useful as the source of specific nucleic acid probes of the invention include but are not limited to corn, rye, wheat (Triticum aestivum and Triticum turdigum) (Column 5, lines 50-58)." Further motivation is provided by Morgante et al as Morgante et al state, "Applicant believe that the method of their invention greatly facilitates the simultaneous identification of multiple genomic polymorphisms, both codominant and dominant. Thus, the present method offers great advantage in identifying polymorphic markers linked to genetic traits of interest, and also offers an efficient and convenient generic technique for genomic fingerprinting and whole genom comparisons (Column 6, lines 6-13). By employing scientific reasoning, an ordinary artisan would have combined and substituted the plants of the Triticum aestivum species of Mets et al. into the method of genotyping plants of Morgante et al. in order to improve the production of specific nucleic acid probes. An ordinary practitioner would have been motivated to combine and substitute the plants of the Triticum aestivum species of Mets et al. into the method of genotyping plants of Morgante et al. in order to achieve the express advantages, as noted by Mets et al., of studying and developing existing crop plants useful as the source of specific nucleic acid probes and also in order to achieve the express advantages, as noted by Morgante et al., of a method that greatly facilitates the simultaneous identification of multiple genomic polymorphisms, both codominant and dominant and offers great advantage in identifying polymorphic markers linked to genetic traits of interest, and also offers an efficient and convenient generic technique for genomic fingerprinting and whole genom comparisons.

Application/Control Number: 08/983,605 Page 5

Art Unit: 1634

### Allowable Subject Matter

4. Claims 15 and 16 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. This objection is based on the absence of any prior art teaching or suggesting the primers having SEQ ID Nos: 1 and 2.

## Response to Amendment

5. In view of the amendment, 112 (second paragraph) rejections are hereby withdrawn and claims 15 and 16 have been objected to.

#### Response to Arguments

6. Applicant's arguments filed on January 30, 2002, have been fully considered but they are not persuasive.

Applicant argued that Morgante reference is not a prior art in view of the German application filed by the applicant on June 28, 1995. Applicant's argument is not persuasive. Applicant is hereby advised and confirmed that the subject matter relied on in the Morgante CIP application (resulting in the patent) was in fact supported in the original parent application (08/346,456), thus providing entitlement to consideration as a 102(e) reference as of the 1994 date. In order to overcome Morgante reference, the applicant must submit 131 declaration by

Page 6

Art Unit: 1634

providing evidence that applicant's invention was practically in use and available in USA before November 28, 1994 (the date of filing of Morgante's original parent application (08/346,456)).

In response to applicant's argument that the references fail to show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e., prior knowledge of SSR locus) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). Applicant also argues that there is no motivation to combine the references. Applicant's argument is not persuasive, especially in the presence of strong motivation provided by Mets et al. since Mets et al. state, "Existing crop plants useful as the source of specific nucleic acid probes of the invention include but are not limited to corn, rye, wheat (Triticum aestivum and Triticum turdigum) (Column 5, lines 50-58)." Further motivation is provided by Morgante et al as Morgante et al state, "Applicant believe that the method of their invention greatly facilitates the simultaneous identification of multiple genomic polymorphisms, both codominant and dominant. Thus, the present method offers great advantage in identifying polymorphic markers linked to genetic traits of interest, and also offers

Page 7

Art Unit: 1634

an efficient and convenient generic technique for genomic fingerprinting and whole genom comparisons (Column 6, lines 6-13)".

Applicant argues that Morgante reference teaches away from the claimed invention because "the entire process is time consuming, expensive, and technically demanding and as a result has been somewhat limited in its application" (Column 3, lines 52-54). Applicant argues that because Ghosh has a preferred embodiment of disadvantages of the method. Ghosh is limited to the preferred embodiment. This argument is not persuasive. As MPEP 2123 states "Disclosed examples and preferred embodiments do not constitute a teaching away from a broader disclosure or nonpreferred embodiments. In re Susi, 169 USPO 423 (CCPA 1971)." MPEP 2123 also states "A reference may be relied upon for all that it would have reasonably suggested to one having ordinary skill the art, including nonpreferred embodiments. Merck & Co. v. Biocraft Laboratories, 10 USPQ2d 1843 (Fed. Cir. 1989)." It is clear that simply because Ghosh has a preferred embodiment, this embodiment does not prevent the reference from suggesting broader embodiments in the disclosure and that this does not constitute a teaching away. Although Ghosh reference uses polyacrylamide in the form of beads of varying pore sizes to purify the nucleotides, the property of running gel electrophoresis is inherently present in this chemically and structurally identical molecule. For example, Ghosh teaches that such polyacrylamide supports or beads can be subjected to gel electrophoresis (Column 2, line 18). Moreover, MPEP 2111 states, "Claims must be given their broadest reasonable interpretation. During patent examination, the pending claims must be "given the broadest

Application/Control Number: 08/983,605 Page 8

Art Unit: 1634

reasonable interpretation consistent with the specification". Applicant always has the opportunity to amend the claims during prosecution and broad interpretation by the examiner reduces the possibility that the claim, once issued, will be interpreted more broadly than it is justified. *In re Prater*, 415 F.2d 1393, 1404-05, 162 USPQ 541, 550-51 (CCPA 1969)". In this case, Morgante reference teaches an alternative method and states, "SSR polymorphism can be detected by PCR using minute amounts of genomic DNA and, unlike RAPDs, they provide codominant markers and can detect a high degree of genetic polymorphism (Column 3, lines 35-38)".

Therefore, all 103 (a) rejections made in the first office action is hereby properly maintained.

#### Conclusion

7. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CAR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CAR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Page 9

Art Unit: 1634

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Arun Chakrabarti, Ph.D., whose telephone number is (703) 306-5818. The examiner can normally be reached on 7:00 AM-4:30 PM from Monday to Friday. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (703) 308-1152. The fax phone number for this Group is (703) 305-7401. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group analyst Chantae Dessau, whose telephone number is (703) 605-1237.

Arun Chakrabarti,

Patent Examiner,

April 9, 2002

Supervisory Patent Examiner Technology Center 1600